Not Yet Recruiting

Metastatic hormone‑sensitive prostate cancer (mHSPC)

Bayer Identifier:

23276

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available

A study of darolutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer in India

Trial purpose

This study will follow patients with metastatic hormone-sensitive prostate cancer in India who receive darolutamide plus androgen deprivation therapy as part of routine medical care. The study aims to describe the real-world safety profile of darolutamide plus androgen deprivation therapy over up to 1 year of follow-up, including adverse events, serious adverse events, adverse events categorized as special topics, treatment changes, and changes in laboratory values, vital signs, and Eastern Cooperative Oncology Group performance status.

Key Participants Requirements

Sex

Male

Age

18 - N/A (No Limit)

Inclusion Criteria

• Men over the age of 18 years
• Histologically or cytologically confirmed adenocarcinoma of prostate
• Metastatic disease (metastatic hormone sensitive prostate cancer) documented by either by a positive bone scan, or for soft tissue either by contrast-enhanced abdominal/pelvic/chest computed tomography (CT) or magnetic resonance imaging (MRI) scan assessed by investigators
• The decision to initiate treatment with darolutamide plus androgen deprivation therapy (ADT) was made as per the investigator’s routine treatment practice
• Written informed consent

Exclusion Criteria

• Participation in an interventional clinical trial program with interventions outside of routine clinical practice
• Any condition that, in investigator’s opinion, precludes reliable safety follow‑up.
• Concomitant use or planned to start the use of docetaxel/any other androgen receptor inhibitors/radiation therapy/chemotherapy or immunotherapy
• Known hypersensitivity to the study drug or any of its ingredients
• Metastatic castration resistant prostate cancer (mCRPC) disease

Trial summary

Enrollment Goal

Trial Dates

October 2026 - October 2028

Phase

Phase IV

Could I Receive a placebo

Products

Darolutamide, BAY 1841788

Accepts Healthy Volunteer

Primary Outcome

Incidence and severity of adverse events and serious adverse events
Occurrence of adverse events, including AE/SAE terms, dates, severity as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0, causality, outcome, actions taken, and seriousness criteria
Time Frame:
From first application of darolutamide after enrollment through the observation period, including up to 30 days after the last dose of darolutamide within the study period, for a total duration of approximately 13 months
Incidence of discontinuations and dose modifications of study drug due to adverse events
Adverse event-related drug discontinuations/modifications, including adverse events leading to dose modification/discontinuation, dates, and reason
Time Frame:
From first application of darolutamide after enrollment through the observation period, including up to 30 days after the last dose of darolutamide within the study period, for a total duration of approximately 13 months

Secondary Outcome

Changes in laboratory parameters
Values at each visit for all laboratory analytes, including haematology, clinical chemistry, urinalysis, and any additional tests performed at the Investigator’s discretion, along with corresponding change-from-baseline metrics and abnormality assessments
Time Frame:
Baseline, follow-up visits, and end of observation visit, over a total duration of approximately 12 months
Changes in Eastern Cooperative Oncology Group performance status and vitals
Time Frame:
Baseline, follow-up visits, and end of observation visit, over a total duration of approximately 12 months
Incidence and severity of adverse events categorized as special topics
Occurrence of adverse events categorized as special topics, including category, severity as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0, causality, actions taken, hospitalization, and discontinuation. Special topics are defined as: • hypertension • vasodilatation and flushing • diabetes mellitus and hyperglycemia • cardiac arrhythmias • fatigue • rash • bone fracture, excluding pathological fractures • coronary artery disorders • decreased weight • mental-impairment disorder • falls, including accident • heart failure • depressed-mood disorder • seizures • gynecomastia • cerebral ischemia.
Time Frame:
From first application of darolutamide after enrollment through the observation period, including up to 30 days after the last dose of darolutamide within the study period, for a total duration of approximately 13 months
Drug administration status
Drug exposure and modifications, including start/stop dates, dose, interruptions, reductions, discontinuation reasons, and cumulative dose
Time Frame:
From baseline/first dose through the treatment and observation period, over a total duration of approximately 12 months

Trial design

An active Post Marketing Surveillance (PMS) observational study of darolutamide in patients with metastatic hormone-sensitive prostate cancer(mHSPC)

Trial Type

Observational

Intervention Type

Drug

Trial Purpose

N/A

Allocation

N/A

Blinding

Open Label

Assignment

N/A

Trial Arms

N/A